Kedokteran & Kesehatan editorial
Open AccessOA2025
Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial
In a single-arm phase 2 trial, omitting breast surgery in patients with residual lesions <2 cm after neoadjuvant therapy who achieved pathologic complete response on vacuum-assisted biopsy resulted in 0% ipsilateral breast tumor recurrence at 5 years. Confirmatory studies are needed before changing practice.
H. Kuerer; V. Valero; Benjamin D. Smith; S. Krishnamurthy; E. Diego; H. Johnson; Heather Y. Lin; Yu Shen; A. Lucci; S. Shaitelman; M. Mitchell; J. Boughey; R. White; K. Hunt; Wei Yang; G. Rauch; T. Moseley; Jessica W. T. Leung; Monica L. Huang; R. Candelaria; B. Adrada; Elsa M. Arribas; R. V. L. van la Parra; D. Ramirez; M. Teshome; Rosa F. Hwang; Makesha V. Miggins; Matthew J. Piotrowski; Ana Refinetti; R. Ehlers; J. Mouabbi; Jessica Suarez-Colen; C. Loveland-Jones; Beth Ann Lesnikowski; L. Samiian; C. Chong; Dalliah M. Black; Sarah M. Desyder; Susie X. Sun; K. Hunt; T. M. Nguyenยท JAMA Oncologyยท 2025ยท DOI 10.1001/jamaoncol.2025.0207
The core problem
Neoadjuvant systemic therapy (NST) achieves pathologic complete response (pCR) in up to 60% of breast cancers, raising the question of whether surgery can be safely omitted in patients who respond well. This trial was designed to evaluate the feasibility of radiotherapy alone without breast surgery in patients selected by image-guided vacuum-assisted biopsy (VAB). The primary objective was to report preplanned 5-year efficacy outcomes, specifically ipsilateral breast tumor recurrence (IBTR), in patients with cT1-2N0-1M0 ERBB2-positive or triple-negative invasive breast cancer who had residual breast lesions <2 cm on imaging after NST.
Innovation
This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers from March 6, 2017, to November 9, 2021. Eligible women were aged 40 years or older with cT1-2N0-1M0 ERBB2-positive (formerly HER2-positive) or triple-negative invasive breast cancer and residual breast lesions <2 cm on imaging after NST. Image-guided VAB of the tumor bed (9G, minimum 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer on VAB underwent standard breast and axillary surgery. Follow-up included physical examinations and mammography every 6 months. The primary outcome was IBTR. Data analysis was performed from October to December 2024.
Introduction
Neoadjuvant systemic therapy (NST) achieves pathologic complete response (pCR) in up to 60% of breast cancers, raising the question of whether surgery can be safely omitted in patients who respond well. This trial was designed to evaluate the feasibility of radiotherapy alone without breast surgery in patients selected by image-guided vacuum-assisted biopsy (VAB). The primary objective was to report preplanned 5-year efficacy outcomes, specifically ipsilateral breast tumor recurrence (IBTR), in patients with cT1-2N0-1M0 ERBB2-positive or triple-negative invasive breast cancer who had residual breast lesions <2 cm on imaging after NST.
Why it matters
The findings suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences observed at 5 years. The high rate of breast pCR on VAB (62%) and the absence of IBTR in patients treated with radiotherapy alone support the potential for a surgery-free approach in this carefully selected population. However, the single-arm design, small sample size, and short follow-up limit the generalizability of the results. The authors conclude that more confirmatory studies are necessary before this new approach alters surgical practice. The trial was registered with ClinicalTrials.gov (NCT02945579).
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ